Pulmonary disease severity in men with ΔF508 cystic fibrosis and residual chloride secretion (vol 353, pg 984, 1999)

被引：0
|
作者：
Thomas, SR
机构：
来源：
LANCET | 1999年 / 353卷 / 9166期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1804 / 1804
页数：1
相关论文
共 44 条
  • [21] Autosomal dominant polycystic kidney disease (ADPKD) and ΔF508 mutation at the cystic fibrosis transmembrane conductance regulator gene.
    Peces, R
    Coto, E
    Gago, E
    Ariza, M
    Laures, AS
    Tejada, F
    Alvarez, J
    KIDNEY INTERNATIONAL, 1999, 55 (01) : 359 - 359
  • [22] Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients
    Derichs, N
    Mekus, F
    Bronsveld, I
    Bijman, J
    Veeze, HJ
    Von der Hardt, H
    Tümmler, B
    Ballmann, M
    PEDIATRIC RESEARCH, 2004, 55 (01) : 69 - 75
  • [23] Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-Mediated Residual Chloride Secretion Does Not Protect against Early Chronic Pseudomonas aeruginosa Infection in F508del Homozygous Cystic Fibrosis Patients
    Nico Derichs
    Frauke Mekus
    Inez Bronsveld
    Jan Bijman
    Henk J Veeze
    Horst von der Hardt
    Burkhard Tümmler
    Manfred Ballmann
    Pediatric Research, 2004, 55 : 69 - 75
  • [24] TAS2R38 GENOTYPE CORRELATES WITH AGE AND CHRONICITY OF PSEUDOMONAL PULMONARY COLONIZATION IN THE ΔF508 HOMOZYGOUS CYSTIC FIBROSIS POPULATION
    Adappa, N. D.
    Cohen, N. A.
    Dorgan, D.
    Frame, D.
    Brooks, S.
    Hadjiliadis, D.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 249 - 249
  • [25] An association study on contrasting cystic fibrosis endophenotypes recognizes KRT8 but not KRT18 as a modifier of cystic fibrosis disease severity and CFTR mediated residual chloride secretion
    Stanke, Frauke
    Hedtfeld, Silke
    Becker, Tim
    Tuemmler, Burkhard
    BMC MEDICAL GENETICS, 2011, 12
  • [26] Phenylglycine and sulfonamide correctors of defective ΔF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating
    Pedemonte, N
    Sonawane, ND
    Taddei, A
    Hu, J
    Zegarra-Moran, O
    Suen, YF
    Robins, LI
    Dicus, CW
    Willenbring, D
    Nantz, MH
    Kurth, MJ
    Galietta, LJV
    Verkman, AS
    MOLECULAR PHARMACOLOGY, 2005, 67 (05) : 1797 - 1807
  • [27] Benzimidazolone activators of chloride secretion: Potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease
    Singh, S
    Syme, CA
    Singh, AK
    Devor, DC
    Bridges, RJ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 296 (02): : 600 - 611
  • [28] DELTA-F508 GENOTYPE DOES NOT PREDICT DISEASE SEVERITY IN AN ETHNICALLY DIVERSE CYSTIC-FIBROSIS POPULATION
    LESTER, LA
    KRAUT, J
    LLOYDSTILL, J
    KARRISON, T
    MOTT, C
    BILLSTRAND, C
    LEMKE, A
    OBER, C
    PEDIATRICS, 1994, 93 (01) : 114 - 118
  • [29] RETRACTED: Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the ΔF508 mutation (Retracted Article. See vol 283, pg 25103, 2008)
    Treharne, Kate J.
    Crawford, Russell M.
    Xu, Zhe
    Chen, Jeng-Haur
    Best, O. Giles
    Schulte, Eva A.
    Gruenert, Dieter C.
    Wilson, Stuart M.
    Sheppard, David N.
    Kunzelmann, Karl
    Mehta, Anil
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (14) : 10804 - 10813
  • [30] Cystic fibrosis transmembrane conductance regulator:: Solution structures of peptides based on the Phe508 region, the most common site of disease-causing ΔF508 mutation
    Massiah, MA
    Ko, YH
    Pedersen, PL
    Mildvan, AS
    BIOCHEMISTRY, 1999, 38 (23) : 7453 - 7461
12345